was obtained from Pfizer Pharmaceuticals, Groton, CT, USA. Ciprofloxacin was deformulated by SmithKline Beecham Pharmaceuticals, and reserpine and ofloxacin were obtained from Sigma Chemical Co., St Louis, MO, USA.
Isolates
S. pneumoniae isolates with ofloxacin MICs of у4 mg/L were obtained from the 1992-1998 Alexander Project, 10 the 1996 SENTRY 11 and SPAR 12 surveillance studies, the 1997 ALERT 13 surveillance project and the University of Iowa (Iowa City, IA, USA) and SB Clinical Laboratories (West Norriton, PA, USA). S. pneumoniae isolates with ofloxacin MICs of Ͻ4 mg/L were selected at random from the 1998 Alexander Project.
Media
MICs were determined using the NCCLS method for broth microdilution 14 with cation-adjusted Mueller-Hinton broth (Becton Dickinson, Cockeysville, MD, USA) with 5% lysed horse blood (Becton Dickinson). Reserpine inhibition studies were carried out in Todd-Hewitt broth supplemented with 5% yeast extract (Becton Dickinson). Reserpine 80 mg/L was added to inocula to inhibit proton motive force efflux pump activity.
Microdilution
MICs were determined by broth microdilution in accordance with NCCLS recommended procedures.
14 Where appropriate, reserpine 80 mg/L was added to the medium to inhibit efflux pump activity. All MIC determinations were carried out in triplicate.
Doubling dilution series were prepared for test compounds in 96-well microtitre plates. The dilution ranges used were 2-0.002 mg/L for gemifloxacin and 32-0.03 mg/L for trovafloxacin, ciprofloxacin and ofloxacin. A positive growth control well, containing medium and test isolate, was included on each plate. A 10 L sample of test medium from the positive growth control well was plated to determine the purity of the test isolate.
Isolation of S. pneumoniae chromosomal DNA
Chromosomal DNA was prepared by resuspending a single plated colony in 1 mL sterile water. Cells were then pelleted and the supernatant removed. Pellets were mixed with 200 L chelating matrix (6% Bio-Rad InstaGene Matrix; Bio-Rad Labs, Hercules, CA, USA) incubated at 56°C for 30 min, mixed by vortex and then lysed in a 100°C water bath for 8 min. The mixture was mixed by vortex again, centrifuged and then added directly to the PCR reaction (20 L supernatant per 50 L PCR reaction).
Each 50 L PCR reaction contained 200 ng of DNA, 1ϫ PCR buffer, 2.0 mM MgCl 2 , 200 M of each deoxynucleoside triphosphate, 100 pmol of each primer and 2.5 U of Taq DNA polymerase (Life Technologies, Rockville, MD, USA). The target gene was amplified by 35 cycles at 95°C for 45 s, 53°C for 30 s and 72°C for 90 s. A final incubation step with an additional 10 min at 72°C was used. Amplified products were checked by agarose gel electrophoresis, then purified using Qiagen QIA quick spin columns (Quiagen Inc., Valencia, CA, USA). The primers used to amplify the gyrA, gyrB, parC and parE genes were as follows:
gyrA_pcr1, 5Ј-TTAAAAAACTTTGTCACGAATATGCC-3Ј; gyrA_pcr2, 5Ј-AACGATACGCTCACGACCAGT-3Ј; gyrB_pcr1, 5Ј-TGAAGGACAAACCAAGACCAAA-3Ј; gyrB_pcr2, 5Ј-GTCCATTTCACCTAGCCCCTTATA-3Ј; parC_pcr1, 5Ј-AAAACCTACTCTACATTCTTTGAAAGGAG-3Ј; parC_pcr2, 5Ј-CAGTTGGGTGGTCAATCATGTAAA-3Ј; parE_pcr1, 5Ј-AGGTTCAGACTATCGTGAGGGACTAGC-3Ј; parE_pcr2, 5Ј-CCGACTCTAATTTCCAGTTTACTAAC-3Ј.
DNA sequencing
PCR products were prepared for automated DNA sequencing using an ABI Prism 377 DNA sequencer (Perkin-Elmer ABI, Foster City, CA, USA). Cycle sequencing reactions were carried out with 50 ng DNA and 3.2 pmol primer using the BigDye Terminator Cycle Sequencing Ready Reaction Kit (Perkin-Elmer ABI). The oligonucleotides used to prime these DNA sequencing reactions were as follows:
gyrA_F1, 5Ј-CGTTTTAGTGGTTTAGAGGC-3Ј; gyrA_R1, 5Ј-GACCAACTTCACTGCATCA-3Ј; gyrB_F1, 5Ј-TTCTCCGATTTCCTCATG-3Ј; gyrB_R1, 5Ј-CCCGGCTGGATATATTCT-3Ј; parC_F1, 5Ј-CGCCCTAGATACTGTGTGA-3Ј; parC_R1, 5Ј-AAATCCCAGTCGAACCAT-3Ј; parE_F1, 5Ј-TGTGGATGGAATAGTGGC-3Ј; parE_R1, 5Ј-ACCGAACTGTTTACGGAGT-3Ј.
The DNA sequences were assembled and edited with Sequencher V3.0 (Gene Codes Corp., Ann Arbor, MI, USA).
Results
Of the 93 isolates reported here, the 12 most susceptible had ofloxacin MICs of 0.125-0.5 mg/L (Table I ). In general, these 12 isolates showed no amino acid changes within the QRDRs of GyrA, GyrB, ParC or ParE, although two isolates did show a Ser114ǞGly substitution in GyrA and the double substitution of Ser52ǞGly ϩ Asn91ǞAsp in ParC. These same substitutions were also found in three strains with MICs of 1-4 mg/L, but as they appeared to have no effect on the MICs for susceptible isolates they are assumed to be silent. Similarly, a number of seemingly silent substitutions were found outside the QRDR region of ParE in strains of all susceptibilities. The most common of these was Ile460ǞVal, but His351ǞLeu, His347ǞLeu and Cys329ǞSer were also found, usually together. Ofloxacin is not pumped out by efflux to any great extent, but four of these 12 strains (33.3%) showed a reserpineinhibitable efflux mechanism which generally doubled the ofloxacin MIC.
Only two of the 15 strains with an ofloxacin MIC of 1-2 mg/L had a substitution in ParC (one Ser79ǞTyr and one Asp83ǞTyr), and all had wild-type GyrA, GyrB and ParE. This group was notable for the high incidence of efflux observed. Ofloxacin efflux was observed in about one-third of the population overall, but in this MIC group 87% of strains (13/15) showed an efflux mechanism which increased the ofloxacin MIC from 0.5 to 1 mg/L.
In the 21 strains with ofloxacin MICs of 4-8 mg/L, no substitutions were found in GyrA or GyrB and only one showed a change in ParE. Most showed a single amino acid substitution in the QRDR of ParC, either Ser79ǞPhe, Ser79ǞTyr or Asp83ǞAsn. For the 20 single-step mutants included in this study, 13 were found at the modal MIC of 4 mg/L (range 1-32 mg/L). One strain with wild-type GyrA and ParC did have an Asp435ǞAsn substitution in ParE which may account for the slightly higher MIC for this strain (4 mg/L). One isolate had the double ParC substitution of Ser52ǞGly ϩ Asn91ǞAsp, assumed to have no impact on the MIC (see above), but this and two other isolates had no detectable substitutions that might explain the ofloxacin MICs of 4 mg/L.
Of the 45 strains with ofloxacin MICs of у16 mg/L, all but two had single substitutions in both GyrA and ParC. The most common GyrA substitution was Ser81ǞPhe (32/45 isolates), but five strains had a Ser81ǞTyr substitution and six a Glu85ǞLys substitution. The most common ParC substitution was Ser79ǞPhe (32/45 strains), but Ser79ǞTyr, Asp83ǞAsn and Arg95ǞCys substitutions were also seen (in nine, three and one of the 45 strains, respectively). The highest MICs were for the two strains with GyrA and ParC substitutions of Ser81ǞTyr and Ser79ǞPhe, respectively.
Two isolates with ofloxacin MICs of 32 and 16 mg/L had no substitutions in GyrA and a single substitution in ParC (Ser79ǞTyr). No significant efflux of ofloxacin was seen for either of these isolates, though their efflux of ciprofloxacin was higher.
In general, amino acid substitutions within the QRDRs of ParC and GyrA have much the same effect on the MICs of gemifloxacin, trovafloxacin and ciprofloxacin as they have on ofloxacin. The major differences seen between antimicrobial agents are the range of MICs and degree of efflux activity. Ciprofloxacin Efflux of trovafloxacin and ofloxacin in this study was low. Only 40% of isolates showed efflux, and in most cases the result was a doubling of the MIC. Gemifloxacin efflux occurred in 55% of all isolates (Table II) , with two-thirds of this group showing a doubling of MIC and the remainder a four-to eight-fold increase. Ciprofloxacin efflux occurred in almost all isolates, including the most susceptible (Table  III) , with most isolates showing at least a four-fold increase in MIC attributable to efflux. The four isolates with the greatest ciprofloxacin efflux were, interestingly, the four isolates with ofloxacin MICs of 4 mg/L and no discernible target mutations.
The susceptibility of these isolates to trovafloxacin (р0.016-16 mg/L) was also determined. Trovafloxacin was more potent than ciprofloxacin and ofloxacin but was generally about 8-to 16-fold less active than gemifloxacin. Trovafloxacin efflux was low, like that of ofloxacin.
Discussion
There have been a number of reports of a two-step mechanism of acquisition of quinolone resistance in S. pneumoniae; the first step is associated with an amino acid substitution in ParC and the second with an additional substitution in GyrA, 6,15-17 although there is evidence that some quinolones select for a first mutation in gyrA. 18, 19 In this study, all clinical isolates showed a first-step mutation in the QRDR of ParC, with a higher level of resistance arising after a second mutation in the QRDR of gyrA.This does not imply that the primary mutational site for gemifloxacin is parC. In fact, it is likely to be gyrA. 20 The most effective, and most common, substitutions appear to be Ser79ǞPhe in ParC and Ser81ǞTyr in GyrA, and the two most resistant isolates in this study had both of these substitutions.
Quinolone resistance in S. pneumoniae as a result of drug efflux has been reported previously 5, 21, 22 and the sequence of one pump, PmrA, has recently been reported. 23 In this study, almost all isolates, including most of the highly susceptible strains, showed some evidence of ciprofloxacin efflux. Most isolates (41%) showed a doubling in MIC, but 33% demonstrated a four-fold increase and 19% у8-fold increase. In only five isolates was the elevated MIC entirely attributable to efflux, and all five had an intermediate susceptibility to ofloxacin (MIC 4 mg/L), with ciprofloxacin MICs of 4-8 mg/L. Ofloxacin and trovafloxacin efflux occurred in about one-third of the isolates in each susceptibility range reported above, but in the group with ofloxacin MICs of 1-2 mg/L, ofloxacin efflux occurred in 80% of isolates. Pan et al. 4 have reported a first-step resistance level which they attribute entirely to reduced permeability, and our results would seem to confirm their findings. The clinical significance of efflux-mediated quinolone resistance in S. pneumoniae is unclear, however.
Susceptibility testing of quinolone-resistant strains to gemifloxacin and other test quinolones revealed that gemifloxacin was the agent least affected by the various resistance mechanisms. Gemifloxacin was the most potent agent tested, and was the only quinolone with MICs of р0.5 mg/L for all strains (MIC range 0.004-0.5 mg/L). These results indicate that gemifloxacin is highly potent against S. pneumoniae, and may also be effective against strains resistant to other quinolones. 
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